About the CRISPR-CAS Technology Session
In the realm of ophthalmology, CRISPR-Cas technology emerges as a transformative force, promising bespoke treatments for a spectrum of ocular ailments. With its precision gene-editing capabilities, CRISPR holds the potential to correct the genetic anomalies underlying inherited retinal diseases like retinitis pigmentosa and Leber congenital amaurosis. Beyond mere correction, it opens avenues for personalized medicine, paving the way for tailored therapies based on an individual's genetic makeup. Despite its immense promise, hurdles such as off-target effects and delivery mechanisms necessitate careful navigation. Nonetheless, CRISPR stands poised to reshape the landscape of ocular care, offering a glimmer of hope to those grappling with vision loss due to currently untreatable conditions.
Topics Covered in CRISPR-CAS Technology
Retinal Dystrophy Gene Editing
CEP290 Editing in LCA
AAV & Nanoparticle Delivery
Off-Target Effects
Base & Prime Editing
Allele-Specific Knockout
Related Scientific Sessions at IOC 2027
Why Attend the CRISPR-CAS Technology Conference 2027
Earn CPD Credit
Sessions are CPD-accredited by The CPD Group (UK) — one CPD credit for every hour of attendance.
Present Your Research
Oral and poster slots for original CRISPR-CAS Technology work, reviewed by the scientific committee.
Network Globally
Meet ophthalmologists, vision scientists, and eye-care clinicians from around the world across three days.
Publish & Get Indexed
Accepted abstracts are compiled into the conference proceedings and indexed in Scopus and Web of Science.
Learn from Keynotes
Plenary lectures from leading voices shaping CRISPR-CAS Technology research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join IOC 2027 for the CRISPR-CAS Technology track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
CRISPR-CAS Technology Conference 2027 — FAQs
What is the CRISPR-CAS Technology track at IOC 2027?
The CRISPR-CAS Technology track is a dedicated stream within IOC 2027 covering the latest research, clinical innovation, and best practice in CRISPR-CAS Technology. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the CRISPR-CAS Technology sessions?
Ophthalmologists, optometrists, vision scientists, educators, doctoral students, and trainees with an interest in CRISPR-CAS Technology are all welcome — whether presenting or attending.
Can I present my research in the CRISPR-CAS Technology track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for CRISPR-CAS Technology sessions?
Yes. IOC 2027 is a hybrid conference — attend the CRISPR-CAS Technology track in person in Singapore or join live online, with on-demand access afterward.
Join the IOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.